Truist Financial Issues Pessimistic Forecast for Biogen (NASDAQ:BIIB) Stock Price

Key Points

• Truist Financial cut its price target on Biogen from $193 to $189 and kept a "hold" rating, with the new target implying roughly an 8.85% upside from the prior close.
• Overall analyst sentiment is a consensus Hold with an average price target of $206.81, based on 12 Buys, 15 Holds and 1 Sell.
• Biogen beat quarterly EPS ($1.99 vs. $1.61 expected) and issued FY2026 guidance of $15.25–$16.25 EPS (street estimate ~15.83 EPS).

Biogen (NASDAQ:BIIB - Get Free Report) had its price target lowered by stock analysts at Truist Financial from $193.00 to $189.00 in a research report issued on Monday,Benzinga reports. The firm currently has a "hold" rating on the biotechnology company's stock. Truist Financial's price target points to a potential upside of 8.85% from the company's previous close.

A number of other equities research analysts also recently weighed in on BIIB. Wolfe Research set a $231.00 target price on Biogen in a report on Monday, February 9th. Tudor Pickering set a $201.00 price target on Biogen in a research note on Monday, February 9th. BMO Capital Markets lifted their target price on Biogen from $165.00 to $196.00 and gave the company a "market perform" rating in a research report on Friday, February 6th. Argus upgraded Biogen to a "hold" rating in a research report on Thursday. Finally, Morgan Stanley lifted their target price on Biogen from $190.00 to $200.00 and gave the company an "equal weight" rating in a research report on Friday. Twelve research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $206.81.

Biogen Stock Performance

Biogen stock traded up $0.67 during mid-day trading on Monday, hitting $173.64. 417,854 shares of the company's stock traded hands, compared to its average volume of 1,327,360. The firm has a 50 day simple moving average of $186.59 and a two-hundred day simple moving average of $172.95. Biogen has a fifty-two week low of $114.66 and a fifty-two week high of $202.41. The stock has a market cap of $25.48 billion, a price-to-earnings ratio of 19.71, a P/E/G ratio of 2.31 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter last year, the firm posted $3.44 EPS. The company's quarterly revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, research analysts expect that Biogen will post 15.83 EPS for the current fiscal year.

Insider Activity at Biogen

In related news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares of the company's stock, valued at $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.18% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Biogen

A number of hedge funds and other institutional investors have recently made changes to their positions in BIIB. Reflection Asset Management acquired a new position in shares of Biogen in the fourth quarter worth approximately $25,000. WPG Advisers LLC lifted its stake in shares of Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company's stock worth $26,000 after acquiring an additional 117 shares during the period. Accredited Wealth Management LLC lifted its stake in shares of Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 185 shares during the period. First Horizon Corp acquired a new position in shares of Biogen in the fourth quarter worth approximately $30,000. Finally, WFA of San Diego LLC acquired a new position in shares of Biogen in the second quarter worth approximately $32,000. 87.93% of the stock is owned by institutional investors and hedge funds.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.